Teva Pharmaceutical

Teva Pharmaceutical Industries Limited (TEVA) – Can TEVA deal with generic competition?

in , , on December 20, 2022

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms, and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical operates as a leader in the development and commercialization of generic and patent medicine used for neurological diseases. The company experienced strong revenue from generics, the market which is being targeted by a number of players.



– Enterprise Value
– CrispIdea Forecast
– Economic Value-Added Analysis
– Discounted Cash Flow Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10-Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

No of Pages: 34

Release Information

  • Price


  • Released

    December 20, 2022

  • Last Updated

    December 26, 2022